CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 175 enrolled
Drug / intervention
NexoBrid +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02148705
NCT02148705Phase 3Completed

A Multicenter, Multinational, Randomized, Controlled, Assessor Blinded Study, Performed in Subjects With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid Compared to Gel Vehicle and Compared to Standard of Care

MediWound Ltd·interventional·Posted May 28, 2014·Updated Jul 10, 2024

In Brief

A Phase 3 clinical trial evaluating NexoBrid, Standard of Care (SOC), and 1 other intervention for Thermal Burns. Completed, enrolled 175 participants across 29 sites in 8 countries.

Detailed Summary

This study will be a three-arms study intending to demonstrate superiority of NexoBrid treatment over the Gel Vehicle placebo control treatment and over SOC in thermal burn subjects. The study objectives are: 1. To demonstrate the efficacy of enzymatic eschar removal with NexoBrid by providing complete eschar removal as compared with Gel vehicle, 2. To demonstrate the efficacy of enzymatic eschar removal with NexoBrid by providing earlier complete eschar removal, reduction in patients' surgical burden and its related blood loss as compared to SOC, 3. To assess the safety of NexoBrid compared to SOC, including demonstration that treatment with NexoBrid does not cause an unacceptable level of harm on wound closure outcome and long term outcomes of cosmesis and function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThermal Burns
CountriesBelgium, Czechia, Georgia, Germany, Israel, Italy, Romania, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 28, 2014
Enrollment StartMay 27, 2015
Primary CompletionJun 12, 2018
Study CompletionAug 20, 2020
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 12.1 years ago

Interventions

NexoBriddrug

Standard of Care (SOC)procedure

Gel Vehicledrug